Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Cohn

Showing results (241-250 of 302) with videos related to

Pageof 31
Sort By:
Cancers|June 2, 2021
Reactivation of Multiple Fetal miRNAs in Lung AdenocarcinomaDavid E Cohn, Mateus C Barros-Filho, Brenda C Minatel, et al.
Gynecologic Oncology|August 7, 2004
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?Scott A Kamelle, Teresa L Rutledge, Todd D Tillmanns, et al.
Cancer Research|March 22, 2019
Inhibition of miR-328-3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian CancerAmit K Srivastava, Ananya Banerjee, Tiantian Cui, et al.
Cancer Research|March 5, 2014
HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancerKellie S Rath, Shan K Naidu, Pushpa Lata, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 16, 2012
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samplesGerard J Nuovo, Michela Garofalo, Nicola Valeri, et al.
Gynecologic Oncology|January 23, 2024
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistanceMonica D Levine, Heather Wang, Bhargavi Sriram, et al.
Gynecologic Oncology|March 8, 2020
Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?Kathryn A Mills, Tanvi V Joshi, Lindsay West, et al.
Neoplasia (New York, N.Y.)|August 21, 2020
Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinomaChristopher S Koivisto, Melodie Parrish, Santosh B Bonala, et al.
Obstetrics and Gynecology|May 2, 2007
Clinical and pathologic correlates in surgical stage II endometrial carcinomaDavid E Cohn, Emily M Woeste, Stacey Cacchio, et al.
Journal of Extracellular Biology|June 28, 2024
ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasisKalpana Deepa Priya Dorayappan, Vincent Wagner, Dongju Park, et al.
Pageof 31

Showing results (241-250 of 302) with videos related to

Sort By:
Pageof 31
Cancers|June 2, 2021
Reactivation of Multiple Fetal miRNAs in Lung AdenocarcinomaDavid E Cohn, Mateus C Barros-Filho, Brenda C Minatel, et al.
Gynecologic Oncology|August 7, 2004
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?Scott A Kamelle, Teresa L Rutledge, Todd D Tillmanns, et al.
Cancer Research|March 22, 2019
Inhibition of miR-328-3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian CancerAmit K Srivastava, Ananya Banerjee, Tiantian Cui, et al.
Cancer Research|March 5, 2014
HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancerKellie S Rath, Shan K Naidu, Pushpa Lata, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 16, 2012
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samplesGerard J Nuovo, Michela Garofalo, Nicola Valeri, et al.
Gynecologic Oncology|January 23, 2024
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistanceMonica D Levine, Heather Wang, Bhargavi Sriram, et al.
Gynecologic Oncology|March 8, 2020
Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?Kathryn A Mills, Tanvi V Joshi, Lindsay West, et al.
Neoplasia (New York, N.Y.)|August 21, 2020
Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinomaChristopher S Koivisto, Melodie Parrish, Santosh B Bonala, et al.
Obstetrics and Gynecology|May 2, 2007
Clinical and pathologic correlates in surgical stage II endometrial carcinomaDavid E Cohn, Emily M Woeste, Stacey Cacchio, et al.
Journal of Extracellular Biology|June 28, 2024
ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasisKalpana Deepa Priya Dorayappan, Vincent Wagner, Dongju Park, et al.
Pageof 31